Better Dividend Growth Stock to Buy: CVS Health or UnitedHealth Group?

UnitedHealth Group is highlighted as the stronger dividend-growth name, with 16 straight years of dividend increases and 10-year annualized dividend growth of 16.6% versus CVS Health's 6.63%. CVS offers the higher forward yield at 2.9% versus UNH's 2.3%, but UNH's dividend is better covered than CVS's reported payout ratio on a GAAP basis. The article is primarily comparative analysis rather than a catalyst-driven update, though it notes CVS trades at 12.5x forward earnings versus 21x for UNH.

Analysis

The market is treating this as a simple yield comparison, but the more important signal is quality of capital return under a stabilizing reimbursement backdrop. UNH’s dividend profile matters less for headline income than for what it implies about free-cash-flow resilience: a company can keep compounding payouts only if the underlying pricing and utilization engine remains intact. CVS looks more interesting as a rerating story, but that upside is conditional on execution holding through several quarters, not just one clean report.

Second-order, the biggest beneficiary of CVS strength may be not CVS itself but the broader managed-care complex: if investors start re-rating a damaged operator on incremental operational improvement, the market will likely become more forgiving on other beaten-up healthcare intermediaries with similar multiple compression. Conversely, UNH’s premium multiple is vulnerable to any evidence that reimbursement normalization is still incomplete; at ~21x forward earnings, the stock needs continued “good enough” fundamentals, not merely adequate ones. That creates asymmetric sensitivity to future guidance revisions over the next 1-2 earnings cycles.

The dividend-growth angle is also a useful screen for duration risk. UNH is effectively a long-duration equity with a bond-like compounding stream, while CVS is a shorter-duration turnaround with higher optionality but lower visibility. In a rate-sensitive market, that distinction matters: if Treasury yields stay elevated, the market may reward CVS’s nearer-term rerating potential more than the steady compounding case, despite inferior dividend growth.

The consensus seems to underweight how much of CVS’s upside is already tied to sentiment normalization, not fundamentals. If operational improvement slows, the stock can give back a lot of that 50% one-year move quickly because the re-rating thesis is still fragile. By contrast, UNH’s downside is more gradual unless reimbursement or medical cost trends materially worsen; the risk there is multiple compression, not dividend failure.

Key Decisions for Investors

• Favor UNH over CVS for income-oriented capital: use a 6-12 month horizon and expect lower total return but higher dividend durability; risk/reward is cleaner if the objective is compounding rather than turnaround beta.
• For upside seekers, buy CVS only on pullbacks after confirmation of the next earnings/guidance cycle; target a modest multiple expansion trade, but size smaller because the thesis depends on continued execution and sentiment repair.
• Pair trade: long CVS / short UNH only as a tactical trade into any reimbursement-driven volatility spike, with a 1-2 quarter holding period; this isolates rerating upside while hedging sector directionality.
• Sell covered calls on UNH against existing longs to harvest premium while capping some upside; appropriate if you expect multiple expansion to remain limited near term.
• Avoid chasing either name after the recent run-up; wait for post-earnings drift or a macro selloff to improve entry, since the next leg higher likely needs a fresh catalyst rather than further multiple rerating alone.